NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Defining and Treating Depression-related Asthma

CompletedEARLY_Phase 1

Sponsor: State University of New York at Buffalo

Conditions: Asthma, Depression, Childhood Asthma

Interventions: Ipratropium Bromide

Countries: United States

Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma. This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depression. The study will also investigate whether the lungs of children with depression and asthma respond to an anticholinergic inhaler called ipratropium more than the lungs of non-depressed asthmatic children.

Eligibility overview

Sex: ALL

Age: 7 Years to 17 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of asthma
* Decreased lung volumes for age/height/race (FEV1 \<80% predicted or ratio of FEV1 to forced vital capacity (FVC) \< 85%) on day of study visit assessed by spirometry.

Exclusion Criteria:

* Severely developmentally delayed patients, or those who suffer from other severe cognitive impairment not allowing them to perform spirometry or participate in study instruments.
* Patients who are pregnant or nursing.
* Patients with significant cardiopulmonary disease other than asthma, including cystic fibrosis, alpha-1-antitrypsin deficiency, interstitial lung disease, tracheo-/bronchomalacia, or cyanotic congenital cardiac defect.
* Patients with glaucoma, myasthenia gravis, or bladder neck obstruction (anticholinergics can worsen these conditions).
* Patients currently taking another anticholinergic medication

Locations (1)

Buffalo, New York, United States